Get started
Author

Alexey E. Vasilyev

Observed names: A. E. Vasiliev, A. Vasiliev, A.G. Vasiliev, Alexey E. Vasiliev
ORCID: 0000-0003-0385-6798
Observed ORCID: 0000-0003-0385-6798
OpenAlex ID: A5059054756
PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
2021 · M. Johnson, B.C. Cho, et al. · Journal of Thoracic Oncology · 50
PDF
The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia
2021 · Tatiana N. Sokolova, Svetlana N. Aleksakhina, et al. · Journal of Modern Oncology · 8
PDF
Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study
2022 · Tatyana N. Sokolova, Tatyana I. Solov'eva, et al. · Journal of Modern Oncology · 3
PDF
Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients
2025 · Tatyana N. Sokolova, Grigory A. Yanus, et al. · Cancers · 1
PDF
Atezolizumab and nab-paclitaxel for advanced triple-negative breast cancer in real-world practice
2025 · I. P. Ganshina, E. V. Artamonova, et al. · Medical alphabet
PDF
P181 Factors influencing prognosis in node-negative early breast cancer (p)T1N0M0
2011 · V.F. Semiglazov, R.M. Paltuev, et al. · The Breast
Works count: 6
Citation count: 62
H-index: 3
I10-index: 1
Year
Topic
Type